Anlotinib in metastatic renal cell carcinoma (mRCC) with a previous anti-VEGFR TKI: Preliminary results from a multicenter, phase II trial.

被引：6
|
作者：
Zhou, Ai-Ping
Bai, Yuxian
Song, Van
Li, Hangzhong
Xie, Xiaodong
Ren, Xiu-Bao
Ye, Dingwei
Liu, Jiyan
Luo, Hong
Bai, Xianzhong
Qin, Shukui
Fu, Cheng
Wang, Jinwan
Ma, Jianhui
机构：
[1] Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China
[2] Harbin Med Univ Canc Hosp, Harbin, Heilongjiang, Peoples R China
[3] Peking Union Med Coll Hosp, Beijing, Peoples R China
[4] Gen Hosp Shenyang Mil Reg, Shenyang, Liaoning, Peoples R China
[5] Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China
[6] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[7] Sichuan Univ, West China Hosp, Dept Abdominal Canc, Ctr Canc, Chengdu, Sichuan, Peoples R China
[8] Chongqing Canc Hosp, Chongqing, Peoples R China
[9] Guangxi Med Univ, Affiliated Tumor Hosp, Nanning, Peoples R China
[10] Nanjing Bayi Hosp, Dept Med Oncol, Nanjing, Jiangsu, Peoples R China
[11] Liaoning Canc Hosp Inst, Shenyang, Liaoning, Peoples R China
[12] Chinese Acad Med Sci, Canc Inst & Hosp, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e16082
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16082
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Estimated cost of adverse event (AE) management for patients (pts) with metastatic renal cell carcinoma (mRCC) treated with a VEGFR TKI.
    Yorio, Jeffrey Thomas
    Asnis-Alibozek, Aviva G.
    Kasturi, Vijay
    Hutson, Thomas E.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [32] Dyamic contrast-enhanced magnetic resonance imaging pharmacodynamic study of sorafenib in metastatic renal cell carcinoma: Preliminary results of a randomized, phase II trial.
    Yang, C.
    Hahn, O.
    Medved, M.
    Karczmar, G.
    Kistner, E.
    Karrison, T.
    Manchen, B.
    Mitchell, M.
    Ratain, M.
    Stadler, W. M.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2007, 55 (02) : S364 - S364
  • [33] RECORD-4: A multicenter, phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Motzer, Robert
    Alyasova, Anna
    Ye, Dingwei
    Karpenko, Andrey
    Li, Hanzhong
    Alekseev, Boris Y.
    Xie, Liping
    Kurteva, Galina Petrova
    Kowalyszyn, Ruben Dario
    Neron, Yeni
    Cosgriff, Thomas
    Collins, LaTonya
    Brechenmacher, Thomas
    Segal, Scott
    Morgan, Liza M.
    Yang, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [34] Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial.
    Choueiri, Toni K.
    Fishman, Mayer N.
    Escudier, Bernard J.
    Kim, Jenny J.
    Kluger, Harriet M.
    Stadler, Walter Michael
    Perez-Gracia, Jose Luis
    McNeel, Douglas G.
    Curti, Brendan D.
    Harrison, Michael Roger
    Plimack, Elizabeth R.
    Appleman, Leonard Joseph
    Fong, Lawrence
    Drake, Charles G.
    Cohen, Lewis J.
    Srivastava, Shivani
    Jure-Kunkel, Maria
    Hong, Quan
    Kurland, John F.
    Sznol, Mario
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [35] Activity of second line axitinib in metastatic renal cell carcinoma (mRCC) patients treated with sunitinib: Results from SAX Italian real world trial.
    Rossetti, Sabrina
    Romano, Francesco Jacopo
    D'Aniello, Carmine
    Cavaliere, Carla
    Pisconti, Salvatore
    Iovane, Gelsomina
    Berretta, Massimiliano
    Marchetti, Paolo
    Crisp, Anna
    Piscitelli, Raffaele
    Muto, Paolo
    Maiolino, Piera
    Perdona, Sisto
    Botti, Gerardo
    Facchini, Gaetano
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [36] Sunitinib expanded-access trial in metastatic renal cell carcinoma (mRCC) - final results from Spain
    Castellano, D.
    Garcia del Muro, X.
    Climent, M. A.
    Maroto, P.
    Perez-Gracia, J. L.
    Lopez-Vivanco, G.
    Zhang, K.
    Fly, K.
    Hariharan, S.
    Anton-Aparicio, L.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S666 - S666
  • [37] Sunitinib in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC): Updated results from a phase I/II study
    Redman, B. G.
    Hudes, G. R.
    Kim, S. T.
    Chen, I.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [38] Camrelizumab plus famitinib for advanced renal cell carcinoma or unresectable urothelial carcinoma: Updated results from a phase II trial.
    Qu, Yuan-Yuan
    Zou, Qing
    Guo, Hongqian
    Xing, Nianzeng
    Sun, Zhongquan
    Han, Weiqing
    Luo, Hong
    Xia, Shujie
    Zhang, Xuepei
    He, Chaohong
    Zhang, Hailiang
    Cai, Jinling
    Zhang, Xiao
    Wang, Quanren
    Ye, Dingwei
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [39] Phase II study of second line pazopanib in patients with metastatic renal cell carcinoma (mRCC) previously treated with a tyrosine kinase inhibitor (TKI).
    Esteban, Emilio
    del Muro, Xavier Garcia
    Sepulveda, Juan Manuel
    Maroto, Pablo
    Diaz, Enrique Gallardo
    del Alba, Aranzazu Gonzalez
    Etxaniz, Olatz
    Guix, Marta
    Gonzalez-Larriba, Jose-Luis
    Arija, Jose Angel Arranz
    Bellmunt, Joaquim
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [40] A phase II study of patients with advanced or metastatic renal cell carcinoma (mRCC) receiving pazopanib after previous checkpoint inhibitor treatment
    Powles, T. B.
    Oudard, S.
    Grunwald, V.
    Calvo, E.
    Michaelson, M. D.
    Burotto, M.
    Melichar, B.
    Tyagi, R.
    Hilmi, F.
    Gaur, A.
    Hirschberg, Y.
    Heng, D.
    ANNALS OF ONCOLOGY, 2020, 31 : S564 - S564
12345